Rifamycin derivatives
    4.
    发明授权
    Rifamycin derivatives 有权
    利福霉素衍生物

    公开(公告)号:US07229996B2

    公开(公告)日:2007-06-12

    申请号:US11186187

    申请日:2005-07-21

    CPC分类号: C07D401/12 C07D455/02

    摘要: Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

    摘要翻译: 式I的新型利福霉素衍生物(氢醌和相应的醌(C 1 -C 4))形成):或其盐,水合物或前药,其中:优选的R 包括氢,乙酰基; L是接头,优选的连接基团元素选自1至5个组的任何组合,如图1所示。 1,其中L不是其中R 1是H,甲基或烷基。 本发明化合物显示出有价值的抗生素性质。 具有这些化合物的制剂可以用于控制或预防哺乳动物,包括人和非人的感染性疾病。 特别地,这些化合物甚至显示出显着的抗菌活性,即使是针对多抗菌菌株的微生物。